Mutz Christopher's Form 4 filing
Ani Pharmaceuticals Inc (ANIP) · filed Mar 10, 2026
- Accession no.
- 0001846487-26-000012
- Filed
- Mar 10, 2026
- Trade date
- Mar 6-9, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions. Open-market sales total $424.6K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mutz ChristopherCIK 0001846487 | Officer (HEAD OF RARE DISEASE) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 6, 2026 | Common Stock | SSaleDisposed | −2,121 | $74.22F2 | −$157,420.62 | 101,387 | Direct | |
| Mar 7, 2026 | Common Stock | FTax withholdingDisposed | −3,314 | $74.04 | −$245,368.56 | 98,073 | Direct | |
| Mar 9, 2026 | Common Stock | SSaleDisposed | −3,602 | $74.18F4 | −$267,196.36 | 94,471 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The shares were sold in multiple trades at prices ranging from $73.14 to $75.00. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.
- F4
The shares were sold in multiple trades at prices ranging from $73.27 to $74.81. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.